R&D

R&D increased by 37%

£6.3m on DepoMorphine

£1.7m on DepoBupivacaine

£1.0m on DepoCyt

R&D target 2002: £26m  DepoMorphine £10m Propofol £ 3m HFA-formoterol £ 4m Funded by PCP transactions

£m

6.7

13.1

17.9

Previous slide

Next slide

Back to first slide

View graphic version